Hormonal
GLP-2 (specifically the analogue teduglutide) promotes intestinal mucosal growth and nutrient absorption, making it an effective treatment for short bowel syndrome (SBS).
For patients with short bowel syndrome who rely on intravenous nutrition, teduglutide (a GLP-2 analogue) is an approved daily injection that helps the intestine grow and absorb more nutrients. This can reduce the need for intravenous feeding. It is specifically designed to resist breakdown in the body, making it effective for chronic use.
GLP-2 as the PGDP with the most potent intestinotrophic activity in mice... Teduglutide was approved for chronic therapy of subjects with PN-dependent SBS in the US in December 2012.
Why this rating
Supported by preclinical studies and Phase 3 clinical trials leading to FDA approval.
Source
Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci97233
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →